natgillin/translations-raw huggingface dataset:
or a pharmaceutically acceptable salt thereof. The compound of claim 8, being in the form of its sodium salt. 
Spoj u skladu s patentnim zahtjevom 12, naznačen time što je u obliku svoje soli s natrijem.
The foil used in this article is typically an aluminum foil of 0.35 mils (0.0089 mm) in thickness, but the thickness and/or the type of metal employed may be varied to achieve any desired degree of heat transfer. 
Folija koja se koristi u ovom proizvodu je tipično aluminijska folija debljine 0.0089 mm, ali se debljina i/ili tip korištenog metala mogu mjenjati za postizanje željenog cfckta prijenosa toplinc.
This example illustrates the cytotoxicity of compounds of this invention against the HL-60 human leukemia cell line in vitro. 
Ovaj primjer ilustrira citotoksicitet spojeva iz izuma protiv HL-60 humane leukemije stanične linije in vitro.
Crystal data were obtained using a Nonius Kappa Charge Coupled Device system at −158° C. The used wavelength was 0.71073 Å. The crystal structure was solved by direct methods and refined by means of SHELX97 in the WinGX package environment. 
Podaci o kristalima dobiveni su koristeći,,Nonius Kapap Charge Coupled Device" sustav pri -158 *C. Korištene valne duljine bile su 0,71073 A. Kristalna je struktura riješena direktnim metodama i pročišćena koristeći okruženje SHELX97 1 paket WinGX .
A pharmaceutical composition comprising a compound of formula I, or free base or other pharmaceutically acceptable salt thereof, and a cytochrome P450 monooxygenase inhibitor or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable excipient, diluent or carrier, wherein the cytochrome P450 monooxygenase inhibitor is ritonavir, or a pharmaceutically acceptable salt thereof. 
Farmaceutski spoj koji se sastoji od spoja formule I ili slobodne baze ili druge farmaceutski prihvatljive soli te inhibitora monooksigenaze citokroma P450 ili njihove farmaceutski prihvatljive soli te barem jedne farmaceutski prihvatljive pomoćne tvari, diluensa ili nosača naznačen time da je inhibitor monooksigenaze citokroma P450 ritonavir ili njegova prihvatljiva farmaceutska sol.
The composition for the use according to claim 10, wherein the composition is for being used in combination with an additional therapeutic agent selected from an immunomodulatory agent, a hormonal agent, a chemotherapeutic agent, an anti-angiogenic agent, an apoptotic agent, a second antibody that binds to and inhibits an inhibitory KIR receptor, an anti-infective agent, a targeting agent and an adjunct compound, wherein said additional therapeutic agent is for being administered as a single dosage form together with said first antibody or as a separate dosage form. 
Oblik prema zahtjevu 43, sadrži lijek koji se koristi u kombinaciji s odgovarajućim dodatnim terapijskim sredstvom izabranim između imunomodulatornog sredstva, hormona, kemoterapijskog sredstva, anti-angiogeničnog sredstva, apoptotičnog sredstva, drugog protutijela koje veže i inhibira inhibitorni KIR receptor, anti-infektivnog sredstva, ciljnog sredstva ili dodatnog spoja gdje se to dodatno terapijsko sredstvo primjenjuje bolesniku kao jedan dozirni oblik zajedno s protutijelom, ili kao posebni dozirni oblik.
The method of claim 1, including providing a continuous length of liner (11, 74, 86, 101) and cutting the liner when the liner is pulled into the predetermined distance from the installation access opening (113). 
Metoda 1z patentnog zahtjeva 1, uključujući opskrbu podloškom neprekinute duljine (11, 74, 86, 101) i rezanje podloška kada je podložak uvučen u predodređenu udaljenost od pristupnog instalacijskog otvora (113).
The pharmaceutical composition of any one of 28 to 36 or 39 to 41, wherein said pharmaceutical composition is a vaccine. 
Farmaceutski pripravak sukladno bilo kojem patentnom od zahtjeva 8 do 12, naznačen time što je navedeni farmaceutski sastav cjepivo.
The method according to any one of claims 1 to 8, wherein the one or more cells is cultured in at least 100 L of the supplemented basal cell culture media. 
Postupak u skladu s bilo kojim od patentnih zahtjeva 1 do 8, naznačen time što se jednu ili više stanica uzgaja u najmanje 100 l kompletiranog osnovnog medija za uzgoj stanica.
A procedure according to claim 6, characterized in that said coupling is achieved by means of adhesives or flame, or ultrasound or stitching. 
Postupak prema zahtjevu 5, naznačen time što se spajanje postiže pomoću adheziva ili plamena, ili ultrazvukom ili šivanjem.
The composition according to any preceding paragraph wherein said hypertonic saline diluent includes NaCl at a concentration of from about 3% to about 7%. 
Pripravak sukladno zahtjevu 11 pri čemu spomenuti hipertonično slano otapalo sadrži NaCl u koncentraciji od 3% do 7%.
In an even more specific embodiment, the present invention is directed to a crystalline sodium salt of Compound (1) that has at least the following characteristic: an X-ray powder diffraction pattern comprising a peak at 10.1 degrees 2θ (±0.2 degrees 2θ) when measured using CuKa radiation. 
Kristalna natrijeva sol prema zahtjevu 2, naznačena time, da ima uzorak difrakcije praha X-zraka koji obuhvaća vršnu vrijednost na 10,1 stupnjeva 20 (+ 0,2 stupnjeva 20) kada se mjeri uporabom radijacije CuKa.
A pharmaceutical composition comprising the monoclonal antibody or antigen binding fragment of claim 1 and a pharmaceutically acceptable excipient. The isolated monoclonal antibody or antigen binding fragment of claim 1, wherein the heavy chain variable region comprises the amino acid sequence set forth as SEQ ID NOs: 25, 26, 27, or 28. 
Protutijelo ili njegov za antigen vezni fragment prema zahtjevu 4 ili 5, gdje je protutijelo ili fragment humanizirano i ima varijabilni teški lanac s barem 75% aminokiselina identičnih aminokiselinskoj sekvenci u SEQ ID NO:25, 26, 27 ili 28.
The composition of claim 1 or 5 in which the first constituent is chemically modified through an amidation with the monomer PA or PRE-PA or a combination of both. 
Sastav prema zahtjevu 1 ili 5, u kojem je prvi sastojak kemijski modificiran kroz amidaciju s monomerom PA 1li PRE-PA ili kombinacijom oba.
The solution was evaporated and the residue dissolved in a mixture of 1:1 trifluoroethanol/methanol (140 ml), and then 2-benzyloxyphenylisocyanide (9.43 g) was added followed by 2-methyl-4-formyloxazole (5.0 g) and the reaction stirred for 4 days at room temperature. 
Otopinu se otpari, a ostatak otopi u 1:1 smjesi trifluoretanol/metanol (140 ml), te se doda 2-benziloksifenil-izocijanid (9,43 g), zatim 2-metil-4-formiloksazol (5,0 g), a reakcijsku smjesu miješa 4 dana na sobnoj temperaturi.
That is, the present invention describes: use of the compound represented by the formula (I-a) or a pharmaceutically acceptable salt thereof for the manufacture of a therapeutic agent for pain; 
PATENTNI ZAHTJEVI Spoj, naznačen time, da je predstavljen sljedećom formulom (1-b) ili njegova farmaceutski prihvatljiva sol koji se upotrebljava za liječenje bolova odabranih od pva bolova 1 fibromialgije:
Further preferred is a method, which comprises applying to the propagation material of the soybean plants a composition comprising a compound of formula (I). 
Pripravak koja je pogodan za kontrolu bolesti koje uzrokuju fitopatogeni, naznačen time što sadrži (A) spoj formule (I)
a heavy chain variable region having at least about 90% sequence identity to SEQ ID NO:50, SEQ ID NO:14, or SEQ ID NO:20; and 
varijabilno područje jakog lanca, koje ima najmanje oko 90% identiteta sekvence od SEQ ID NO:50, SEQ ID NO:14, ili SEQ ID NO:20; i
reacting a compound of the formula IV A-CH2—X IV wherein A is as previously defined and X is a leaving group, with a compound of the formula V wherein Z, n, R3 and R4 are as previously defined; or 
IV gdje A je kao prethodno definiran i X je izlazeća skupina, sa spojem formule V gdje Z,n, R* i R* su kao prethodno definirani; ili
The electrochemical cell electrolyte according to claim 1 or 2, wherein the linear carbonates are selected from the group comprising dimethyl carbonates (DMC), diethyl carbonate (DEC) and ethyl methyl carbonate (EMC). 
Elektrolit za elektrokemijski članak u skladu s patentnim zahtjevom 1 ili 2, naznačen time što se nerazgranate karbonate bira iz skupine koju čine dimetil-karbonati (DMC), dietil-karbonat (DEC) i etil-metil-karbonat (EMC).
scanning said area by means of a ground penetrating radar; identifying obstacles in said area using data generated by said ground penetrating radar; wherein said steps of scanning and identifying are performed before said step of sawing. 
- < skeniranja navedenog područja pomoću radara koji prodire kroz tlo; - identificiranja prepreka u navedenom području pomoću podataka generiranih od navedenog radara koji prodire kroz tlo; naznačeno time da se navedeni koraci skeniranja i identificiranja obavljaju prije navedenog koraka piljenja.
A process for the manufacture of compound I 
Postupak proizvodnje spoja I
The oral suspension is characterized by a lack of bitter taste. 
Oralna suspenzija je karakterizirana manjkom gorkog okusa.
The composition for use according to any one of the preceding claims, further comprising a skin penetration enhancer, wherein the skin penetration enhancer is preferably selected from the group consisting of polyvalent aliphatic C2-C10 alcohols, polyalkylene glycols having C2-C4 alkylene groups, non-alkoxylated ethers of polyvalent aliphatic C2-C10 alcohols and polyalkylene glycols having C2-C4 alkylene groups, azones, terpenes, terpenoides, pyrrolidones, sulfoxides and mixtures thereof, and most preferably is dimethyl sulfoxide. 
Pripravak za primjenu prema bilo kojem od prethodnih zahtjeva, koja i dalje sadrži promotor prodiranja kroz kožu, naznačen time, što se je promotor prodiranja kroz kožu poželjno odabran iz skupine koja se sastoji od polivalentnih alifatskih C2-C19g alkohola, polialkilenskih glikola s C2-C4 alkilenskim grupama, nealkoksiliranih etera polivalentnih alifatskih C>-C;9 alkohola i polialkilenskih glikola s C2-C, alkilenskim grupama, azona, terpena, terpenoida, pirolidona, sulfoksida i njihovih smjesa, a najpoželjnije je dimetil sulfoksid.
allowing said condensed distillate to return to said hydrocarbon processing unit, or to be collected as said product. 
omogućujući navedenom kondenziranom destilatu da se vrati u spomenuto postrojenje za preradu ugljika, ili da bude pokupljen kao narečeni podukt.
The sensor of claim 1, where the reagent composition comprises from about 1 to about 7.5 µg of the binder per mm2 of the working electrode area, from about 16 to 167 nmol, preferably from about 24 to about 84 nmol, of the buffer salt per mm2 of the working electrode area, from about 12 to 100 nmol, preferably from about 20 to about 70 nmol, of the mediator per mm2 of the working electrode area, from about 0.5 to about 5 Units of the enzyme system per mm2 of the working electrode area, and from about 0.3 to about 4.3 µg of the non-ionic surfactant per mm2 of the working electrode area. 
Senzor prema zahtjevu 1, naznačen time da pripravak reagensa sadrži od oko 1 do oko 7.5 µg veziva po mm2 površine radne elektrode, od oko 16 do 167 nmol, poželjno od oko 24 do oko 84 nmol, puferske soli po mm2 površine radne elektrode, od oko 12 do 100 nmol, poželjno od oko 20 do oko 70 nmol, posrednika po mm2 površine radne elektrode, od oko 0.5 do oko 5 jedinica enzimskog sustava po mm2 površine radne elektrode, te od oko 0.3 do oko 4.3 µg ne-ionskog surfaktanta po mm2 površine radne elektrode.
an antibody or antigen-binding fragment thereof according to any one of claims 7 to 12 for the preparation of a pharmaceutical composition for the prevention and or treatment of various diseases involving acute inflammation such as systemic inflammatory response syndrome (SIRS), sepsis, severe sepsis, septic shock, ischemia/reperfusion related injuries such as ischemic heart disease, acute lung injury, pneumonia, acute and chronic graft rejection in transplant patients, graft versus host reactions, as wells as diseases involving chronic types of inflammation such as renal glomerular diseases such as glomerulonephritis and other entities of renal failure, rheumatoid arthritis and similar auto-immune diseases such as Bechterew's disease, lupus-type diseases, inflammatory bowel disease, Crohn's disease, tumor growth, or solid organ cancer. 
antitijela ili njegovog antigen vezujućeg fragmenta prema bilo kojem od zahtjeva 7 do 12 za pripremanje farmaceutske kompozicije radi prevencije i ili liječenja raznih bolesti uključujući akutnu upalu, kao što su sindrom sistemskog upalnog odgovora (SIRS), sepsa, teška sepsa, septički šok, povrede povezane s ishemijom/reperfuzijom, kao što je ishemijska srčana bolest, akutna povreda pluća, upala pluća, akutno i kronično odbacivanje transplantata kod pacijenata s transplantacijom, reakcije transplantata protiv primatelja, kao i bolesti koje sadrže kronične tipove upale, kao što su bubrežne glomerularne bolesti, kao što su glomerulonefritis i druge vrste bubrežne insuficijencije, reumatoidni artritis i slične autoimune bolesti, kao što su Ankilozirajući spondylitis, bolesti tipa lupusa, upalna bolest crijeva, Chronova bolest, rast tumora, ili kancerogenih bolesti organa u tijelu.
Assay Protocol for Determining Receptor Binding for RUP25: 
Protokol ispitivanja za određivanje vezivanja na receptor za rup25
The method according to claim 11, characterised in that the step of connecting the visible portion (3) of the decorative body (2) on the first surface (6) of the supporting sheet (5) is carried out by means of hot-melt gluing. 
- < rezanje potpornog lista (5) na granici dekorativnih tijela (2) na način da perimetrijski rub (13) potpornog lista prati ornamentalni oblik definiran dekorativnim tijelima (2), navedeni korak rezanja provodi se pomoću lasera.
The reagent of claim 1, wherein the final concentration for the at least one chaotrope is from 0.1 Molar to 2 Molar, the final concentration of the at least one kosmotrope is from 0.1 Molar to 2 Molar, the final concentration of the chelator is from 0.1 M to 2 Molar, and the final concentration of the apoptosis substrate is from 0.001 Molar to 0.5 Molar. 
Reagens prema zahtjevu 1, naznačen time da konačna koncentracija barem jednog kaotropa je od 0.1 Molarno do 2 Molarno, konačna koncentracija barem jednog kozmotropa je od 0.1 Molamo do 2 Molarno, konačna koncentracija kelatora je od 0.1 M do 2 Molarno, i konačna koncentracija supstrata apoptoze je od 0.001 Molarno do 0.5 Molarno.
Modular antibody according to any one of claims 1 to 9 for use in therapy. Modular antibody according to any of claims 1 to 10, for use in treating a patient suffering from a solid tumor, which tumor expresses a receptor of the erbB class, wherein the receptor is Her2. 
Modularno protutijelo prema bilo kojem od zahtjeva 1 do 8 ili 12 do 13, ili molekula protutijela prema bilo kojem od zahtjeva 9 do 11, naznačeno/naznačena time, da se upotrebljava u liječenju pacijenta koji boluje od čvrstog tumora, pri čemu tumor izražava receptor iz erbB-razreda.
Prior to assessing turbidity, compositions can be centrifuged or filtered to remove large particles (e.g. 
Prije procjenjivanja zamućenosti, sastav se može centrifugirati ili filtrirati da se odstrane velike čestice (na pr.
Item 1. A compound represented by the formula (I) wherein 
HR P20180483 T1 1. < Spoj, naznačen time, da je predstavljen formulom (I): gdje
The IL-17 antagonist for use according to Claim 18, wherein the dose of each of the IL-17 antagonist and the IL- 23 antagonist is gradually reduced during a second treatment period that begins upon the end of the first treatment period. 
19. IL-17 antagonist za uporabu u skladu sa zahtjevom 18, naznačen time, da se doza svakog od IL-17 antagonista i 1L-23 antagonista postupno smanjuje za vrijeme drugog razdoblja liječenja koje započinje završetkom prvog razdoblja liječenja.
The composition of claim 5 in which the PRE-CC is PHU of 1 to 200'000, preferably 1 to 20'000, CC and PA monomers, terminated by CC monomers, and the PRE-PA is a PHU of 1 to 200'000, preferably 1 to 20'000, CC and PA monomers, terminated by PA monomers. 
Sastav prema zahtjevu 5, u kojem PRE-CC je PHU od 1 do 200'000, poželjno 1 do 20'000, CC 1 PA monomeri, terminirani CC monomerima i PRE-PA je PHU od 1 do 200'000, poželjno 1 do 20000, CC 1 PA monomeri, terminirani PA monomerima.
Once the beverage production process has been completed, the electronic control (not shown in the figures) will control the electric motor 12 to turn in the reverse direction, such that the spindle 15 will retract the shaft 16 such that in turn the mobile brewing head support 7 will be lifted back to the position as shown in Fig. 3. 
Kada se jednom završi postupak proizvodnje napitka, elektronički upravljački sklop (nije prikazan na slikama) će upravljati s elektromotorom 12 tako da on rotira u suprotnom smjeru, HR P20080616 T3 tako da će vratilo 15 vući natrag osovinu 16 pa se zatim nosač pomične glave za pripremanje napitka 7 podigne natrag u položaj koji je prikazan na slici 3.
an outlet for agglomerates (8), and an outlet for product stream (9). 
- izlaz za aglomerate (8), i - < izlaz za struju produkta (9).
In other embodiments, the ingredient comprises a mixture of a hydrophilic solvent, a lipophilic solvent, and an emulsifier. Liquid Formulations 
Formulacija prema zahtjevu 1, naznačena time, da je sastojak mješavina hidrofilnog otapala, lipofilnog otapala i emulzifikatora.
Antibody and antigen-binding fragment according to claim 1 and 2, whereby the antibody consists of an antigen-binding region that binds specifically to or has a high affinity of for one or more regions of PRLR, whose amino acid sequence is depicted by SEQ ID NO: 70 and human polymorphic variants of SEQ ID NO: 70, amino acid position 1 to 210, whereby the affinity is at least 30 nM, more preferred with an affinity of less than about 10 nM, or even more preferred with an affinity of less than 1 nM. 
Antitijelo prema zahtjevu 1 do 2, naznačeno time da se antitijelo sastoji od regije koja veže antigen koja se specifično veže na ili ima visoki afinitet za jednu ili više regija od PRLR, čija je sekvenca amino kiseline prikazana sa SEQ ID NO: 70 i ljudskim polimorfnim varijantama iz SEQ ID NO: 70, položajem amino kiseline 1 do 210, pri čemu je afinitet barem 100 nM, poželjnije s afinitetom od manje od oko 100 nM, poželjnije s afinitetom od manje od oko 30 nM, čak još poželjnije s afinitetom od manje od oko 10 nM, ili čak još poželjnije s afinitetom od manje od 1 nM.
Other means of forming a cam surface 17 are of course possible within the scope of the invention. 
Drugi načini stvaranja nazubljene površine 17 su naravno mogući unutar duha izuma.
Upon cooling, crystals formed which were collected by filtration, washed with a water: methanol (1:1) solution, and dried. 
Nakon hlađenja su nastali kristali koji su skupljeni filtracijom, isprani otopinom voda:metanol (1:1), 1 osušeni.
The two initial doses may be administered not only for one day, but also for 2, 3, 4, 5, 6 or 7 days or even longer. 
Konstrukt namijenjen upotrebi u skladu s patentnim zahtjevom 17, naznačen time što se dvije početne doze primjenjuje 2, 3, 4, 5, 6 ili 7 dana ili čak 1 dulje.
In fact, in the absence of faults in data transmission device 1, the telegrams generated independently by microprocessors 6a, 6b from the same input signals should match. 
Ustvari, u odsutnosti grešaka u napravi za prijenos podataka 1, telegrami generirani nezavisno mikroprocesorima 6a, 6b iz istih ulaznih signala bi se trebali podudarati.
obtaining the iron (III) complex with N-acetyl-L-aspartylated casein. 
(c) dobivanja kompleksa željeza(IIl) s N-acetil-L-aspartiliranim kazeinom.
a nucleotide sequence encoding at least one glycosyltransferase from a Gram-negative bacterium; 
nukleotidni slijed koji kodira najmanje jednu glikozil-transferazu iz Gram-negativne bakterije, gdje je navedena Gram-negativna bakterija Pseudomonas aeruginosa;
• the dose of haemagglutinin per viral strain per single intranasal or inhalational administration is lower or equal to 30 ug, characterized in that no separate adjuvant and/or immune stimulator is added to the composition. 
* > doza haemaglutinina po virusnom soju po jednom intranazalnom ili inhalacijskom davanju je manja ili jednaka 30 ug, naznačen time da nema odvojenog dodavanja adjuvanta i/ili imunološkog stimulatora u pripravak.
is selected from the group consisting of hydrogen, alkyl, arylalkyl, cycloalkyl, cycloalkylalkyl, heterocycle, heteroarylalkyl, and (NRCRD)sulfonyl; and RC and RD are independently selected from the group consisting of hydrogen and alkyl. 
Ri s R2 i R3 vodik; nje 0; Rg je odabran iz skupine koja se sastoji od vodika, alkila. arilalkila, cikloalkila, cikloalkilalkila, heterocikla, heteroarilalkila, 1 (NRcRp)sulfonila; a
The mixture according to claim 13, wherein the antibody is selected from the group consisting of an IgG antibody, an IgA antibody, an IgE antibody, an IgD antibody, and an IgM antibody. 
Mješavina prema zahtjevu 7, naznačena time što je antitijelo odabrano iz skupine koja se sastoji od IgG, IgA, IgE, IgD i IgM.
Figure 13 superimposes the turbidity results of Figure 10 on the SDS removal profile of Figure 12. 
Slika 13 superponira rezultate zamućenja iz Slike 10 na profilu odstranjivanja SDS iz Slike 12.
The present invention generally relates to capsules for containing beverage ingredients, to a beverage producing system comprising such capsules as well as to methods for producing beverages on the basis of ingredients contained in such capsules. 
Predmetni izum se općenito odnosi na čahure koje sadržavaju sastojke za napitke, na sustav za proizvodnju napitka koji sadržavaju takve čahure, kao i na postupak za proizvodnju napitaka na osnovi sastojaka koji su sadržani u takvim čahurama.
Reactions were terminated by the removal of the liquid components of the assay followed by washing of the plates with PBS-T. 
Reakcija se zaustavi uklanjanjem tekućih komponenti testa, nakon čega slijedi ispiranje pločica sa PBS-T-om.
Preferably, said lamellas are fixed on a round, disc-shaped support, whereby the free edges of these lamellas extend practically radially, such that the sanding element forms what is called a laminated disc. 
Poželjno je da su navedene lamele učvršćene na okrugli nosač koji ima oblik diska, pri čemu se slobodni krajevi ovih lamela pružaju praktički radijalno, tako da element za brušenje čini tako zvani lamelirani disk.
In still other embodiments, the salt in the pH buffered saline solution comprises magnesium chloride, potassium chloride, sodium chloride or a combination thereof. 
Silikonizirani spremnik u skladu s bilo kojim od patentnih zahtjeva 1 do 4, naznačen time što sol u pH puferiranoj fiziološkoj otopini sadrži magnezijev klorid, kalijev klorid, natrijev klorid ili njihovu kombinaciju.
Detecting and quantifying said viable microorganisms, in which the microorganisms are of the species Legionella pneumophila, and in which the repair compounds comprise 
detekciju i kvantitativno određivanje navedenih vijabilnih mikroorganizama, pri čemu su mikroorganizmi vrste Legionella pneumophila, i pri čemu spojevi za popravak sadrže
The neck ring arms 14 are fitted with neck rings 172 adapted to engage the neck portion of a glass parison to permit transfer of the glass parison to the blow mold side of the apparatus. 
Hvataljke izdanka kalupa (14) su prilagođene izdanku kalupa (172) koji služi kako bi zahvatio završni dio staklene taline čime se omogućuje prijenos staklene taline na stranu završnog kalupa.
A topical pharmaceutical formulation comprising a compound of formula (I): or salt or solvate thereof for use in the treatment of ocular neovascular disorders by direct administration to the eye. 
CH, (ILO. si: fo m ili njegovu sol ili solvat, naznačena time što je namijenjena upotrebi u liječenju neovaskularnih poremećaja oka izravnom primjenom u oko,